The deal centers on STC-004, a Phase 2-ready Nav1.8 inhibitor targeting chronic pain without the addictive risks of opioids.
Intelligence for the Dealmaking Community since 1965
After clicking on a story, use the back arrow in your browser to return to your search results. Use phrases "in quotes" or the tools below to better filter your results.